EWS_EU: neue psychoaktive Subst. - Fentanylderivate
andrea.bodenwinkler
#1 Geschrieben : Donnerstag, 1. Juni 2017 11:10:59(UTC)
Rang: Advanced Member

Beiträge: 213

Sehr geehrte Fachleute!
Anbei leite ich Ihnen Informationen aus dem Europäischen Informations- und Frühwarnsystem weiter.

In Schweden wurden folgende neue psychoaktive Substanzen identifiziert.

Benzoylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]benzamide): The substance is a synthetic opioid analgesic of the phenylpiperidine chemical class and derivative of fentanyl. It differs from fentanyl due to the presence of a benzene ring in place of the methyl linked to the carboxamide group. Similarly to other fentanils (such as furanylfentanyl) Benzoylfentanyl has an aromatic ring linked to the carboxamide group. The substance was identified in 2 grams of white powder, seized by Swedish Customs at Stockholm on 16 March 2017. The seizure, made at Postnord, Arlanda, originated in Hong Kong and was destined to Malmö. Benzoylfentanyl was analytically confirmed by GC-MSD, LC-HRMS and NMR by the Swedish National Forensic Centre (NFC). There is no published information available on the pharmacology and toxicology of benzoylfentanyl.
3-phenylpropanoylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-3-phenylpropanamide): The substance is a synthetic opioid analgesic of the phenylpiperidine chemical class and derivative of fentanyl. It differs from fentanyl due to the presence of a phenylethyl moiety in place of the methyl linked to the carboxamide group. 3-Phenylpropanoylfentanyl was identified in 2 grams of white powder, seized by Swedish Customs at Stockholm on 16 March 2017. The seizure, made at Postnord, Arlanda, originated in Hong Kong and was destined to Malmö. The substance was analytically confirmed by GC-MSD, LC-HRMS and NMR by the Swedish National Forensic Centre (NFC). 3-3Phenylpropanoylfentanyl is included in a study by Zhu et al. which measures the analgesic activity of derivatives of fentanyl (mouse, intravenous, hot plate test) [Zhu Y-Q et al. 1. Studies on potent analgesics. I. Synthesis and analgesic activity of fentanyl derivatives. Yao Xue Xue Bao. 1981;16(3):199-210.].
4-fluoro-N-ethylpentedrone (2-(ethylamino)-1-(4-fluorophenyl)pentan-1-one): The substance is a higher homologue of 4-fluoroethcathinone (4-FEC), which was formally notified in February 2015. 4-Fluoro-N-ethylpentedrone is also structurally related to α-ethylaminopentiophenone (or N-ethylnorpentedrone), DL-4662 and 4-methyl-N-ethylnorpentedrone (4-MEAP). The four substances have in common an α-ethylaminopentiophenone (i.e. a N-ethylnorpentedrone) core structure, differing on the substituents on the benzene ring. 4-Fluoro-N-ethylpentedrone has a fluoro group at position 2; 4-methyl-N-ethylnorpentedrone has a methyl group at position 4; and DL-4662 has two methoxy groups at positions 3 and 4.The substance contains a stereogenic centre and therefore two possible enantiomers of 4-fluoro-N-ethylpentedrone may exist. 4-Fluoro-N-ethylpentedrone was identified in 930 mg of white powder, seized by Swedish Police at Skellefteå on 26 November 2016. The substance was analytically confirmed GC-MSD, GC-IRD, LC-HRMS and NMR by the Swedish National Forensic Centre (NFC). There is no published information available on the pharmacology and toxicology of 4-fluoro-N-ethylpentedrone.


In Lettland wurde die neue psychoaktive Substanz SDB-006 N-phenyl analogue identifiziert.

SDB-006 N-phenyl analogue (1-pentyl-N-phenyl-1H-indole-3-carboxamide): The substance is the N-phenyl analogue of SDB-006, which was formally notified in 2013. Both substances share a pentyl tail, an indole core and a carboxamide linker. However, the SDB-006 N-phenyl analogue contains a phenyl linked group whereas SDB-006 contains a benzyl linked group. SDB-006 N-phenyl analogue also shares structural similarities with LTI-701, which was formally notified in 2016. The difference in the molecular structures of these two substances is that LTI-701 has a 5-fluoro substituent at the pentyl chain that is absent in the SDB-006 N-phenyl analogue. The three substances (SDB-006 N-phenyl analogue, SDB-006 and LTI-701) are structurally related to APICA. All of them have in common a pentyl tail, an indole core and a carboxamide linker. Reference material of SDB-006 N-phenyl analogue has been characterised analytically by GC-MS, FTIR-ATR and GC-MS-IR [1]. It should be noted that the code name ‘SDB-005’ has been used in the scientific literature to designate 1-pentyl-N-phenyl-1H-indole-3-carboxamide. According to the nomenclature used by the EMCDDA, SDB-005 corresponds to naphthalen-1-yl-1-pentyl-1H-indazole-3-carboxylate. SDB-006 N-phenyl analogue was identified in 1.4904 grams of herbal material, seized by Latvian Police in Riga Central Prison on 16 October 2015. The substance was analytically confirmed by GC-MS by the Forensic service department of the State Police. The substance 1-(5-fluoropentyl)-N-(naphthalen-2-yl)-1H-indole-3-carboxamide (5F-NNEI-2) was also detected in the sample. SDB-006 N-phenyl analogue is a potent synthetic cannabinoid receptor agonist. The synthesis and in vitro functional activity of SDB-006 N-phenyl analogue at rat CB1 and human CB2 receptors have been studied in a paper by Banister et al using the FLIPR membrane potential assay (EC50(CB1) = 21 nM and EC50(CB2) = 140 nM) [2]. The cannabimimetic activity at human CB1 receptor has been studied by the same authors and using the same assay (EC50(CB1) = 116 nM) [3].
[1] NPS and related compounds. Analytical reports. European project RESPONSE to challenges in forensic drugs analyses. Available at: http://www.policija.si/a...D-1606-16_rpt030816.pdf
[2] Banister SD, et al. The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci. 2013;4(7):1081-92.
[3] Banister SD, et al. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci. 2015;6(8):1445-58.



Sollten zu den oben genannten Substanzen Informationen aus Österreich vorliegen, bitten wir um Weiterleitung an ews@goeg.at.

Mit freundlichen Grüßen
Andrea Bodenwinkler


Informations – und Frühwarnsystem über besondere Gesundheitsgefahren im Zusammenhang mit Substanzkonsum
Aktuelle Informationen und Warnungen: https://forum.goeg.at/ewsforum/

Dr. Andrea Bodenwinkler
Gesundheit Österreich GmbH
Stubenring 6
1010 Wien
T: +43 1 515 61-187
F: +43 1 513 84 72
andrea.bodenwinkler@goeg.at
www.goeg.at
ews@goeg.at
Du kannst keine neue Themen in diesem Forum eröffnen.
Du kannst keine Antworten zu Themen in diesem Forum erstellen.
Du darfst deine Beiträge nicht löschen.
Du darfst deine Beiträge nicht editieren.
Du kannst keine Umfragen in diesem Forum erstellen.
Du kannst nicht an Umfragen teilnehmen.

GÖG theme by René Philipp Heindl (GÖG)
Powered by YAF | YAF © 2003-2010, Yet Another Forum.NET